Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Clinical response to anti-tumour necrosis factor alpha treatment in patients with rheumatoid arthritis and anti-Ro/SSA antibodies

From: Anti-tumour necrosis factor alpha treatment in patients affected by rheumatoid arthritis with anti-Ro/SSA antibodies

  Mean Disease Activity Score 44 P
At onset 5.56  
6th month 3.38 0.006
12th month 3.41 0.03
18th month 3.33 0.01
24th month 2.88 0.006